The Continuous Manufacturing Technique, Either For In-house Requirements Or For Contract Service Engagements, Claims Roots Analysis


the continuous manufacturing technique, either for in-house requirements or for contract service engagements, claims Roots Analysis

The COVID-19 pandemic has severely impaired the overall pharmaceutical supply chain, mostly owing to the absence of workers at manufacturing sites and restrictions imposed on distribution networks. In this context, continuous manufacturing offers a viable solution given the fact that continuous processes are largely automated. In fact, the FDA (and other regulatory bodies) have also expressed interest in advocating a shift to the use of advanced manufacturing technologies, such as continuous manufacturing.


To order this 310+ page report, which features 110+ figures and 200+ tables, please visit this -


The USD 1.9 billion (by 2030) financial opportunity within the continuous manufacturing market has been analyzed across the following segments:

  • Purpose of Manufacturing
  • In-House
  • Contract service


  • Scale of Operation
  • Commercial
  • Preclinical / Clinical


  • Type of Continuous Manufacturing related Service
  • API Manufacturing
  • End Product manufacturing


  • Type of Drug Molecule
  • Biologic
  • Small Molecule


  • Type of dosage form
  • Solid
  • Liquid


  • Key Geographical Regions
  • North America
  • Europe
  • Asia Pacific


The Manufacturing Market Continuous (Small Molecules and Biologics), 2020 – 2030.” report features the following companies, which we identified to be key players in this domain:

  • AbbVie Contract Manufacturing
  • Ajinomoto Bio-Pharma Services
  • Almac
  • Boehringer Ingelheim BioXcellence
  • Cambrex
  • CordonPharma
  • Hovione
  • Kaneka
  • Lonza
  • Patheon
  • SK biotek


Table of Contents


  1. Preface

    2. Executive Summary

  2. Introduction

  3. Market Landscape

  4. Companies with Expertise in Continuous Manufacturing in North America: Profiles

  5. Companies with Expertise in Continuous Manufacturing in Europe: Profiles

  6. Companies with Expertise in Continuous Manufacturing in Asia-Pacific: Profiles

  7. Recent Partnerships and Collaborations

  8. Recent Expansions

  9. Capacity Analysis

  10. Academic Grant Analysis

  11. Patent Analysis

  12. Initiatives of Companies with In-House Continuous Manufacturing Capabilities

  13. Case Study: Modular Facilities in pharmaceutical / Biotechnological Industry


  1. Case Study: Technology and Equipment Providers


  1. Case Study: Roadmap for the Adoption of Continuous Manufacturing Processes


  1. Market Forecast and Opportunity Analysis


  1. Conclusion


  1. Executive Insights


  1. Appendix 1: Tabulated Data


  1. Appendix 2: List of Companies and Organizations


To purchase a copy, please visit


Contact Details

Gaurav Chaudhary

+1 (415) 800 3415 


Keywords: roots analysis,research,pharma,biotech,analysis,market research,industry reports,business report


Other related blogs

The subcutaneous biologic drugs and affiliated technologies market is projected to be worth over USD 180 billion by 2030

By : Roots Analysis

Roots Analysis has done a detailed report on Subcutaneous Biologics, Technologies and Drug..

The subcutaneous biologic drugs and affiliated technologies market is projected to be worth over USD 180 billion by 2030, predicts Roots Analysis

By : Roots Analysis

Subcutaneous drug delivery, given the use of tailored formulation development solutions, has brought..

Medical Device Labels Manufacturing Market, 2019-2030

By : Roots Analysis

To order this detailed 300+ page report, please visit this-